NMN/NAD+ enhances SIRT2-modulated microtubule dynamics to improve mitochondrial and mitophagy functions in senescent cells

As cells age, they accumulate damaged mitochondria that can no longer be efficiently repaired or cleared away. This study, published in Autophagy (2026), identifies a previously unrecognized chain of events linking the NAD+ precursor NMN to a cytoplasmic enzyme called SIRT2, which controls the flexibility of the cell's internal skeleton (microtubules). In senescent muscle cells, low NAD+ levels silence SIRT2, causing tubulin proteins to become over-decorated with acetyl groups, which locks microtubules into a rigid, hyper-stable state. That rigidity physically impairs the cell's ability to move, repair, or dispose of damaged mitochondria through the mitophagy recycling pathway. The resulting mitochondrial debris leaks mitochondrial DNA into the cytoplasm, triggering the cGAS-STING1 innate-immune alarm and accelerating cellular senescence. When the researchers supplemented senescent muscle cells with NMN, SIRT2 was reactivated, microtubule dynamics were restored, mitophagy resumed, and cGAS-STING1 signaling was dampened. The work establishes a SIRT2–microtubule axis as a distinct, mechanistically tractable target for combating age-related mitochondrial decline—separate from the better-known SIRT1 and SIRT3 pathways that NAD+ boosters are usually credited with activating.

• Senescent muscle cells show microtubule hyper-stabilization accompanied by SIRT2 inactivation and tubulin hyperacetylation; this rigid cytoskeletal state causally impairs mitochondrial movement, fission/fusion balance, and mitophagy flux.
• Microtubule dysfunction in senescent cells leads to mtDNA leakage into the cytoplasm, activating the cGAS-STING1 innate-immune pathway, which the authors demonstrate further accelerates the senescence program.
• NMN treatment reactivates SIRT2, normalizes microtubule acetylation and dynamics, restores mitochondrial quality-control capacity (repair and mitophagy), suppresses cGAS-STING1 signaling, and thereby mitigates senescence markers—identifying a protective mechanism that extends beyond the canonical NAD+-SIRT1/SIRT3 axis.

This is a mechanistic cell-biology study conducted in human senescent muscle cells (likely D-galactose-induced and/or replicative senescence models, as noted in the abbreviations list). The study employed SIRT2 gain- and loss-of-function manipulations alongside NMN supplementation, with readouts including tubulin acetylation assays, live-cell microtubule dynamics imaging, mitochondrial morphology and function assays, mitophagy flux assays (LAMP1 co-localization), mtDNA cytoplasmic leakage quantification, and cGAS-STING1 pathway activation markers. Senescence was assessed via SA-β-gal staining and EdU proliferation assays. Specific sample sizes (number of biological replicates or animal numbers) and NMN dosing concentrations are not reported in the abstract.

Because this study is conducted in cultured senescent muscle cells (and potentially D-galactose-treated models), it is unclear whether the SIRT2–microtubule–mitophagy axis operates equivalently in vivo in aged organisms or in non-muscle tissues. The abstract does not report in vivo validation, so the translational relevance to systemic NMN supplementation in humans or animals remains to be established. NMN raises both NAD+ and downstream metabolites, so it is not possible from these data alone to rule out SIRT2-independent contributions to the observed phenotypic rescue. A key next experiment would be to perform SIRT2-specific knockout or pharmacological inhibition in an aged animal model treated with NMN, to confirm that microtubule re-dynamization is necessary for the mitophagy and senescence benefits observed.

This study directly extends [§99], which similarly targets mitochondrial RNA/DNA leakage and cGAS-STING-driven inflammation as a driver of aging, but via a distinct mechanism (mitochondrial RNA suppression rather than microtubule-dependent mitophagy restoration), together suggesting that multiple upstream bottlenecks converge on innate-immune activation in senescent cells. It parallels [§116] in demonstrating that mitochondrial quality-control deficits accumulate in aging tissues through enzyme-level regulatory failures—ALDH2 deficiency in that case, SIRT2 inactivation here—and that correcting the upstream enzyme rescues downstream mitochondrial homeostasis. The PINK1/Parkin-linked mitophagy context explored in [§134] provides a complementary mechanistic frame, since the cytoskeletal machinery described here is likely required for autophagosome–lysosome trafficking regardless of which mitophagy receptor initiates the process. This work also parallels [§136], which demonstrates that enhancing mitophagy flux (via hirudin in peripheral nerve cells) suppresses NLRP3 inflammasome activation—a conceptually analogous inflammasome-adjacent innate-immune consequence of impaired mitochondrial clearance, reinforcing the broader principle that restoring mitophagy competence is anti-inflammatory across diverse cell types.

• Mitigating Mitochondrial RNA Release During Aging to Control Inflammation and Senescence
  Most direct thematic overlap: both articles target NAD+-related pathways to suppress cGAS-STING innate-immune signaling and mitigate senescence through mitochondrial quality control, making the mechanistic differences (microtubule dynamics vs. mitochondrial RNA release) directly instructive.
• Impact of aldehyde dehydrogenase 2 deficiency on tissue-specific mitochondrial metabolism in aging mice
  Useful contrast: both identify an age-associated loss of a mitochondria-protective enzyme (SIRT2 here; ALDH2 there) as the proximal cause of mitochondrial dysfunction, but in different tissues and via different biochemical cascades, helping readers assess how generalizable enzyme-rescue strategies are across aging contexts.
• Cardiomyocyte BMAL1 deficiency worsens obesity-related cardiomyopathy with heightened PINK1/Parkin-linked mitophagy and mitochondrial dysfunction
  Complementary mitophagy-pathway comparison: BMAL1-regulated PINK1/Parkin mitophagy in cardiomyocytes versus SIRT2-regulated microtubule-dependent mitophagy in muscle cells—comparing the two illuminates how circadian and cytoskeletal inputs independently gate the same quality-control outcome.
• Hirudin Promotes Peripheral Nerve Repair by Enhancing Mitophagy to Suppress NLRP3 Inflammasome Activation
  Parallel functional endpoint: hirudin restores mitophagy to suppress NLRP3 inflammasome in nerve repair, while NMN restores mitophagy to suppress cGAS-STING in senescent muscle—juxtaposing these articles clarifies how the same mitophagy-to-innate-immunity logic plays out across different inflammatory effectors and tissues.
• Diphlorethohydroxycarmalol isolated from <i>Ishige okamurae</i> improves age-related muscle dysfunction by Ca<sup>2+</sup>-dependent response <i>via</i> the SirT1/PGC-1α pathway <i>in vitro</i> and <i>i
  Same target tissue and aging phenotype: this article addresses age-related muscle dysfunction through a different compound (diphlorethohydroxycarmalol), allowing readers to compare molecular entry points and downstream mitochondrial outcomes in skeletal muscle senescence.